The most useful anatomical landmarks for identifying Schlemm's intra-operatively include the scleral spur and pigmented meshwork, if present.
Trabectome
The Trabectome (see Figure 1) , approved by the US Food and Drug Administration (FDA), permits ab interno trabeculotomy-including ablation of a strip of trabecular meshwork and the inner wall of Schlemm's canalwith simultaneous aspiration and irrigation to remove tissue debris while maintaining a stable anterior chamber.
1,2 The device includes a ceramiccoated insulated footplate that acts as a glide within Schlemm's, and also protects adjacent tissues from heat or mechanical injury.
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This procedure is performed through a clear 1.6mm near-limbal temporal corneal incision under direct gonioscopic control via a modified Swan-Jacob goniolens (see Figure 2 ). The goal is to unroof a 90-120º arc of Schlemm's by removing the meshwork, juxtacanalicular connective tissue, and inner wall of the canal, allowing direct aqueous access to collector channels in the posterior canal wall. A foot-pedal control maintains aspiration and ablation at constant levels. An infusion sleeve allows continuous or intermittent inflow of fluid. Ablation power and aspiration rates are adjustable.
The most useful anatomical landmarks for identifying Schlemm's intra-operatively include the scleral spur and pigmented meshwork, if present.
Alternatively, blood in Schlemm's canal after installation of viscoelastic into the anterior chamber often clearly marks the location of Schlemm's. The inferior nasal quadrant is specifically targeted as collector channels are thought to be most numerous there. As ablation proceeds, the back wall of Schlemm's appears as a white band in the trail of the instrument's footplate.
Back bleeding from exposed collector channels or Schlemm's typically occurs during the latter part of canal opening or when IOP drops as the instrument is removed. Back bleeding typically stops spontaneously over several minutes, or when an internal tamponade is installed via fluid or an air bubble. Only rarely among the more than 400 procedures performed and reported so far has the resulting hyphema been more than 10-20%, persisted for more than a few days, or been associated with a postoperative IOP spike. Intra-operative back bleeding may be decreased by pre-operative use of apraclonidine. Ocucoat ® has proved to be a satisfactory viscoelastic when required, and seems to be relatively easily cleared from the anterior chamber. A single 10-0 nylon or polyglactin suture has been routinely placed across the corneal wound.
Post-operatively, most eyes have been treated with 1% pilocarpine twice daily for two weeks, and pre-operative medications resumed temporarily • Glaucoma is the second leading cause of blindness in the world.
• There will be 60.5 million people with open-angle glaucoma and angleclosure glaucoma by 2010, increasing to 79.6 million by 2020.
• Women will comprise 55% of open-angle glaucoma cases, 70% of angle-closure glaucoma cases, and 59% of all glaucoma cases by 2010.
• End-stage glaucoma costs patients approximately $2,511 per annum.
The cost of medication was responsible for one-third to half of the total direct patient cost.
• African-Americans aged 45-65 are 14-17 times more likely to go blind from glaucoma than Caucasians with glaucoma in the same age group.
• Studies suggest that there is a correlation between glaucoma and systemic hypertension. 
